Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px
Document › Details

Karolinska Development AB. (2/24/17). "Press Release: Karolinska Development Notes Oncopeptides' Successful Listing on Nasdaq Stockholm". Stockholm.

Region Region Stockholm
  Country Sweden
Organisations Organisation Karolinska Development AB (Nasdaq Stockholm: KDEV)
  Organisation 2 Oncopeptides AB (Nasdaq Stockholm: ONCO)
  Group Oncopeptides (Group)
Products Product cancer drug
  Product 2 investment banking
Index term Index term Oncopeptides–SEVERAL: investment, 201702 IPO €72.5m at Nasdaq Stockholm
Persons Person Van Heusden, Jim (Karolinska Development –201706 CEO LEFT 10/17)
  Person 2 Tange, Christian (Karolinska Development 2014–201712 CFO LEFT 12/17)

Karolinska Development AB (Nasdaq Stockholm: KDEV) notes the successful initial public offering ("IPO") of Oncopeptides AB on Nasdaq Stockholm. Karolinska Development has a 5% earn-out agreement for Oncopeptides with Industrifonden that has a current market value of SEK 26.7 million based on Oncopeptide's market capitalisation at listing on February 22.

Oncopeptides AB is a clinical development stage pharmaceutical company developing drugs for treatment of cancer and a former Karolinska Development portfolio company in which Karolinska Development retains an economic interest.

In 2012, Karolinska Development exchanged its holding of shares in Oncopeptides for Industrifonden's holding of shares in Aprea. The transaction also included a provision that would give Karolinska Development a 5% share of any revenue Industrifonden receives from its holdings of Oncopeptides up to a maximum of SEK 80 million. The 5% share represents a market value of SEK 26.7 million based on Oncopeptide's market capitalisation at listing on February 22. The transaction also allowed for a similar provision for Industrifonden which will receive a 5% share of any revenue Karolinska Development receives from its holding of Aprea up to a maximum of SEK 80 million.

Jim Van heusden, CEO of Karolinska Development, said: "We congratulate Oncopeptides for completing its IPO successfully and wish management every success as it begins its life as a public company. From Karolinska Development's perspective, this milestone provides a clear indication of the value potential that the company has retained in companies that were formerly part of its portfolio through earn-out agreements, and which are making important progress with the support of their new owners, investors and shareholders."

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail:
Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail:

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail:


About Karolinska Development AB

Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients' lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.

For more information, please visit

Record changed: 2017-03-01


Picture [iito] Plain Stupid Simple 650x80px

More documents for Karolinska Development AB (Nasdaq Stockholm: KDEV)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px

» top